What is PPD?
Founded in 1985, Pharmaceutical Product Development (PPD) operates as a leading contract research organization (CRO). PPD provides comprehensive drug discovery, development, and lifecycle management services to a diverse clientele, including pharmaceutical, biotechnological, and medical device companies, as well as academic and governmental organizations. The company's extensive expertise supports clients through the complex journey of bringing new therapies to market, positioning it as a critical partner in the global healthcare innovation landscape.
How much funding has PPD raised?
PPD has raised a total of $2.2B across 2 funding rounds:
Other Financing Round
$550M
Stock Offering
$1.6B
Other Financing Round (2017): $550M with participation from Hellman & Friedman and GIC
Stock Issuance/Offering (2020): $1.6B, investors not publicly disclosed
Key Investors in PPD
Hellman & Friedman
Hellman & Friedman is a private equity firm established in 1984, specializing in buyouts, restructurings, and diverse investment strategies across sectors including financial services, health care, and information services.
GIC
GIC, a sovereign wealth fund founded in 1981, manages Singapore's foreign reserves and invests globally across public and private markets to ensure long-term financial security.
What's next for PPD?
The substantial enterprise-level capital infusion and recent strategic investment indicate PPD's strong market position and its capacity for further innovation and service expansion. This backing is expected to fuel advancements in drug development technologies and broaden the company's service offerings. PPD is poised to leverage this financial strength to enhance its capabilities in clinical research, data analytics, and regulatory support, solidifying its leadership in the CRO sector and contributing to the advancement of global health solutions.
See full PPD company page
